calcitonin has been researched along with Postoperative-Complications* in 4 studies
2 trial(s) available for calcitonin and Postoperative-Complications
Article | Year |
---|---|
Salmon calcitonin (Miacalcic ns 200 IU) in prevention of bone loss after hip replacement.
Loosening of a hip prosthesis after total arthroplasty is related to periprosthetic bone loss. Calcitonin has been used in the treatment of bone loss in osteoporosis and prevention of fractures. The main purposes of the study were firstly to evaluate the effect of calcitonin on periprosthetic bone after total hip arthroplasty, secondly investigate possible loosening of the prosthesis and thirdly examine further clinical outcome.. 60 patients who underwent total hip arthroplasty using cemented Exeter prosthesis were randomized in the treatment group (salmon calcitonin 200 IU nasal spray daily + calcium 500 mg) and the placebo group (inactive nasal spray + calcium 500 mg) for six months. Bone mineral density (BMD) was measured from different locations at the time of discharge and after six and 12 months. Dynamic histomorphometry on bone biopsies taken from femoral collum was performed. Serum bone-specific alkaline phosphatase (BAP), serum osteocalcine (OC) and cross-linked N-telopeptides (NTX) were measured after one week, one month, three months and 12 months. Clinical manifestations and the incidence of fractures and loosening of the prosthesis were followed up to eight years.. Statistically there was not significant difference in bone histomorphometry between the groups. In both groups there was a significant BMD decrease in periprosthetic bone. However, the difference between the groups was not statistically significant. In the biochemical analysis NTX increased more in the Miacalcic group than in the placebo group (pā=ā0.013). There were no significant differences between the groups in serum BAP or OC even though the changes within the groups were statistically significant. No loosening of the prosthesis was seen during the follow-up and there was no need for revision of any reason. Four fractures were recorded in three patients. One patient sustained a periprosthetic fracture. All the patients with fractures were allocated in the placebo group.. Nasal salmon calcitonin 200 IU on a daily basis does not promote any additional value on calcium substitution to prevent bone loss after hip replacement. The durability of the Exeter prosthesis was good. Topics: Arthroplasty, Replacement, Hip; Bone Density Conservation Agents; Calcitonin; Drug Administration Schedule; Female; Follow-Up Studies; Hip Prosthesis; Humans; Incidence; Male; Nasal Sprays; Osteoporosis; Periprosthetic Fractures; Postoperative Complications; Prosthesis Failure; Treatment Outcome | 2012 |
Calcitonin and bisphosphonates treatment in bone loss after liver transplantation.
Osteopenia is a major complication of orthotopic liver transplantation (OLT). However, no effective therapy for bone disease has been defined. We have studied vertebral bone mineral density (VMD) and fasting serum markers of bone formation [bone gla protein (BGP), procollagen I carboxyterminal peptide (PICP)] and metabolism (serum Ca, P, intact parathyroid hormone (iPTH), 25OHD3 and 1,25(OH)2D3) in 120 patents after OLT. VMD was measured by dual-energy X-ray absorptiometry (DXA) using a Hologic QDR 1000 densitometer on two occasions, 12 months apart. Patients with OLT had a VBD significantly lower compared with age- and sexed-matched Spanish controls (P < 0.05). Prevalence of osteoporosis (Z score below -2 SD) was 35.8%. Serum BGP (8.6 +/- 0.7 ng/ml) and PICP (222.9 +/- 81.9 ng/dl) were higher than those of controls. However, serum calcium, phosphorus, iPTH, 25OHD3, and 1,25(OH)2D3 were within normal range. Patients with osteoporosis were randomly treated with 40 IU/day of calcitonin i.m. (Diatin, Ferrer Int. Laboratories) (n = 17) or 400 mg p.o., 15 days every 3 months, of sodium ethiodronate (Difosfen, Rubio Laboratories) (n = 23). All patients received 500 mg/12 hours of elemental calcium p.o. After 12 months of treatment, a significant increment of vertebral mineral density (VMD) was observed (6.4% and 8.2%, respectively). Serum BGP and PICP values remained elevated without a difference between the two drugs. Our results indicate that antiresorptive drugs may be of benefit in the high turnover osteoporosis of OLT recipients. Topics: Adult; Bone Density; Bone Diseases, Metabolic; Calcitonin; Etidronic Acid; Female; Humans; Liver Transplantation; Male; Middle Aged; Osteoporosis; Postoperative Complications | 1995 |
2 other study(ies) available for calcitonin and Postoperative-Complications
Article | Year |
---|---|
Rapid postoperative osteolysis in Paget disease. A case report.
Topics: Aged; Analgesics; Calcitonin; Early Ambulation; Femoral Neck Fractures; Fractures, Spontaneous; Hip Prosthesis; Humans; Male; Osteitis Deformans; Osteolysis; Postoperative Complications; Radiography | 1994 |
Malignant osteopetrosis: hypercalcaemia after bone marrow transplantation.
A 3 year old girl presented with malignant osteopetrosis, which was treated by allogeneic bone marrow transplantation. Successful engraftment was complicated by prolonged hypercalcaemia, which was controlled by a combination of a bisphosphonate, phosphate infusions, vigorous resalination, and salmon calcitonin. She was alive and well 16 months after the transplant. Topics: Bone Marrow Transplantation; Calcitonin; Child, Preschool; Diphosphonates; Female; Humans; Hypercalcemia; Osteopetrosis; Pamidronate; Phosphates; Postoperative Complications | 1991 |